Kinetics of small molecule inhibitor binding to p38 kinase

Robin L. Thurmond, Scott A. Wadsworth, Peter H. Schafer, Robert A. Zivin, John Siekierka

Research output: Contribution to journalArticleResearchpeer-review

46 Citations (Scopus)

Abstract

p38 mitogen-activated protein kinase (MAPK) (p38/p38-α/CSBP2/RK) has been implicated in the regulation of many proinflammatory pathways. Because of this, it has received much attention as a potential drug target for controlling diseases such as rheumatoid arthritis, endotoxic shock, inflammatory bowel disease, osteoporosis, and many others. A number of small molecule inhibitors of this kinase have been described, and in this paper we have used surface plasmon resonance to directly measure and quantitate their binding to p38. Despite the relatively low molecular mass (≈ 400 Da) of these inhibitors, specific binding can be observed. For the two most potent inhibitors studied, SB 203580 and RWJ 67657, dissociation constants, Kd's, of 22 and 10 nM, respectively, were obtained. These values closely match the IC50 values observed in a cell-based TNFα release assay implying that p38 plays a major role in TNFα release. The association and dissociation rates for the binding of these inhibitors to p38 have also been quantitated. SB 203580 and RWJ 67657 have very similar association rates of around 8 × 105 M-1·S-1, and the differences in affinity are determined by different dissociation rates. The weaker binding compounds have dissociation rates similar to SB 203580, but the association rates vary by an order of magnitude or more. The direct measurement of compounds binding to p38 may help in understanding the difference between potency and efficacy for these inhibitors. This in turn may yield clues on how to develop better inhibitors.

Original languageEnglish
Pages (from-to)5747-5754
Number of pages8
JournalEuropean Journal of Biochemistry
Volume268
Issue number22
DOIs
StatePublished - 3 Dec 2001

Fingerprint

Phosphotransferases
p38 Mitogen-Activated Protein Kinases
Molecules
Kinetics
Association reactions
Surface Plasmon Resonance
Septic Shock
Inflammatory Bowel Diseases
Inhibitory Concentration 50
Osteoporosis
Rheumatoid Arthritis
Molecular mass
Surface plasmon resonance
Assays
Pharmaceutical Preparations
SB 203580
RWJ 67657

Keywords

  • BIAcore
  • Kinetics
  • Surface plasmon resonance
  • TNFα
  • p38 kinase

Cite this

Thurmond, Robin L. ; Wadsworth, Scott A. ; Schafer, Peter H. ; Zivin, Robert A. ; Siekierka, John. / Kinetics of small molecule inhibitor binding to p38 kinase. In: European Journal of Biochemistry. 2001 ; Vol. 268, No. 22. pp. 5747-5754.
@article{03af595e1fd44090b2f7df080d775b3e,
title = "Kinetics of small molecule inhibitor binding to p38 kinase",
abstract = "p38 mitogen-activated protein kinase (MAPK) (p38/p38-α/CSBP2/RK) has been implicated in the regulation of many proinflammatory pathways. Because of this, it has received much attention as a potential drug target for controlling diseases such as rheumatoid arthritis, endotoxic shock, inflammatory bowel disease, osteoporosis, and many others. A number of small molecule inhibitors of this kinase have been described, and in this paper we have used surface plasmon resonance to directly measure and quantitate their binding to p38. Despite the relatively low molecular mass (≈ 400 Da) of these inhibitors, specific binding can be observed. For the two most potent inhibitors studied, SB 203580 and RWJ 67657, dissociation constants, Kd's, of 22 and 10 nM, respectively, were obtained. These values closely match the IC50 values observed in a cell-based TNFα release assay implying that p38 plays a major role in TNFα release. The association and dissociation rates for the binding of these inhibitors to p38 have also been quantitated. SB 203580 and RWJ 67657 have very similar association rates of around 8 × 105 M-1·S-1, and the differences in affinity are determined by different dissociation rates. The weaker binding compounds have dissociation rates similar to SB 203580, but the association rates vary by an order of magnitude or more. The direct measurement of compounds binding to p38 may help in understanding the difference between potency and efficacy for these inhibitors. This in turn may yield clues on how to develop better inhibitors.",
keywords = "BIAcore, Kinetics, Surface plasmon resonance, TNFα, p38 kinase",
author = "Thurmond, {Robin L.} and Wadsworth, {Scott A.} and Schafer, {Peter H.} and Zivin, {Robert A.} and John Siekierka",
year = "2001",
month = "12",
day = "3",
doi = "10.1046/j.0014-2956.2001.02512.x",
language = "English",
volume = "268",
pages = "5747--5754",
journal = "European Journal of Biochemistry",
issn = "0014-2956",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "22",

}

Kinetics of small molecule inhibitor binding to p38 kinase. / Thurmond, Robin L.; Wadsworth, Scott A.; Schafer, Peter H.; Zivin, Robert A.; Siekierka, John.

In: European Journal of Biochemistry, Vol. 268, No. 22, 03.12.2001, p. 5747-5754.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Kinetics of small molecule inhibitor binding to p38 kinase

AU - Thurmond, Robin L.

AU - Wadsworth, Scott A.

AU - Schafer, Peter H.

AU - Zivin, Robert A.

AU - Siekierka, John

PY - 2001/12/3

Y1 - 2001/12/3

N2 - p38 mitogen-activated protein kinase (MAPK) (p38/p38-α/CSBP2/RK) has been implicated in the regulation of many proinflammatory pathways. Because of this, it has received much attention as a potential drug target for controlling diseases such as rheumatoid arthritis, endotoxic shock, inflammatory bowel disease, osteoporosis, and many others. A number of small molecule inhibitors of this kinase have been described, and in this paper we have used surface plasmon resonance to directly measure and quantitate their binding to p38. Despite the relatively low molecular mass (≈ 400 Da) of these inhibitors, specific binding can be observed. For the two most potent inhibitors studied, SB 203580 and RWJ 67657, dissociation constants, Kd's, of 22 and 10 nM, respectively, were obtained. These values closely match the IC50 values observed in a cell-based TNFα release assay implying that p38 plays a major role in TNFα release. The association and dissociation rates for the binding of these inhibitors to p38 have also been quantitated. SB 203580 and RWJ 67657 have very similar association rates of around 8 × 105 M-1·S-1, and the differences in affinity are determined by different dissociation rates. The weaker binding compounds have dissociation rates similar to SB 203580, but the association rates vary by an order of magnitude or more. The direct measurement of compounds binding to p38 may help in understanding the difference between potency and efficacy for these inhibitors. This in turn may yield clues on how to develop better inhibitors.

AB - p38 mitogen-activated protein kinase (MAPK) (p38/p38-α/CSBP2/RK) has been implicated in the regulation of many proinflammatory pathways. Because of this, it has received much attention as a potential drug target for controlling diseases such as rheumatoid arthritis, endotoxic shock, inflammatory bowel disease, osteoporosis, and many others. A number of small molecule inhibitors of this kinase have been described, and in this paper we have used surface plasmon resonance to directly measure and quantitate their binding to p38. Despite the relatively low molecular mass (≈ 400 Da) of these inhibitors, specific binding can be observed. For the two most potent inhibitors studied, SB 203580 and RWJ 67657, dissociation constants, Kd's, of 22 and 10 nM, respectively, were obtained. These values closely match the IC50 values observed in a cell-based TNFα release assay implying that p38 plays a major role in TNFα release. The association and dissociation rates for the binding of these inhibitors to p38 have also been quantitated. SB 203580 and RWJ 67657 have very similar association rates of around 8 × 105 M-1·S-1, and the differences in affinity are determined by different dissociation rates. The weaker binding compounds have dissociation rates similar to SB 203580, but the association rates vary by an order of magnitude or more. The direct measurement of compounds binding to p38 may help in understanding the difference between potency and efficacy for these inhibitors. This in turn may yield clues on how to develop better inhibitors.

KW - BIAcore

KW - Kinetics

KW - Surface plasmon resonance

KW - TNFα

KW - p38 kinase

UR - http://www.scopus.com/inward/record.url?scp=0035171919&partnerID=8YFLogxK

U2 - 10.1046/j.0014-2956.2001.02512.x

DO - 10.1046/j.0014-2956.2001.02512.x

M3 - Article

VL - 268

SP - 5747

EP - 5754

JO - European Journal of Biochemistry

JF - European Journal of Biochemistry

SN - 0014-2956

IS - 22

ER -